主要研究方向为淋巴瘤及造血干细胞移植。

基础研究：近期研究集中在淋巴瘤免疫微环境与免疫调控，在研项目：国家自然科学基金，81970188，HADC抑制剂对外周T细胞淋巴瘤PD-1/PD-L1免疫逃逸信号通路调控机理的研究；北京市自然科学基金，20G10757，HDACi调节PD-1+细胞MMP-9表达而增强PD-1单抗在T淋巴瘤中的疗效。

临床研究：组织多项研究者发起的单中心或多中心临床研究，包括西达苯胺联合CHOEP方案治疗初治外周T细胞淋巴瘤；来那度胺、利妥昔单抗、大剂量甲氨蝶呤治疗原发初治中枢神经系统淋巴瘤等。

近年代表论文：

1. A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide:Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From PatientsWith PTCL. Frontier in oncology .

2. Gut Microbiota in Untreated Diffuse Large B CellLymphoma Patients. FrontMicrobiol 2021 

3. Thecombination of chidamide with the CHOEP regimen in previously untreatedpatients with peripheral T-cell lymphoma: a prospective, multicenter, singlearm, phase 1b/2 study.  Cancer Biol Med. 2021 

4. Prognostic value of interim 18F-FDG PET/CT in T-cell lymphomas. Leuk Lymphoma. 2020;61(4):927-933

5. Clinical characteristics and prognostic factors in Chinese patients with classical Hodgkin's lymphoma involving extranodal sites: a retrospective single-center. Hematology.2019;24:661-668

6. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) associated with or without lymphoma: Comparison of clinical features and risk factors suggestive of underlying lymphomas. J Clin Neurosci. 2019 Aug;66:156-164.

7. Autoimmune disease-associated non-Hodgkin's lymphoma-a large retrospective study from China. Ann Hematol. 2019;98(2):445-455

8. The optimal timing of radiotherapy in the combined modality therapy for limited-stage extranodal NK/T cell lymphoma (ENKTL): a systematic review and meta-analysis. Ann Hematol. 2018;97(12):2279-2287

9. Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma. Leuk Res. 2018

10. Patients with Fever of Unknown Origin and Splenomegaly: Diagnostic Value of Splenectomy and Preoperative Risk Factors Suggestive of Underlying Lymphomas. Acta Haematol. 2017;137(4):240-246

11. Circulating PD-1(+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1(+) cells. Cancer Med. 2018 doi:10.1002/cam4.2097.